Outlook Therapeutics, Inc. quarterly report, Q2 FY2018

Outlook Therapeutics, Inc. (then Oncobiologics, Inc.) — Form 10-Q Summary

Reporting period: Fiscal second quarter and six months ended March 31, 2018. The interim financial statements are unaudited. The company is a clinical-stage monoclonal-antibody therapeutics developer and had no approved products or product sales.

Financial performance and position

Metric	Three months ended March 31, 2018	Six months ended March 31, 2018
Collaboration revenue	$771,890	$1.54 million
Research and development expense	$5.16 million	$5.56 million
General and administrative expense	$2.45 million	$6.00 million
Operating loss	$6.83 million	$10.01 million
Net loss	$7.54 million	$9.46 million
Net loss attributable to common stockholders	$8.56 million	$26.28 million
Basic loss per share	$0.33	$1.04

Revenue was entirely collaboration revenue, principally deferred upfront payments recognized over time; it does not represent product sales. Product gross margins are therefore not meaningful in this period.

At March 31, cash was $5.94 million; current assets were $6.92 million and current liabilities were $31.75 million. Total assets were $27.79 million and total liabilities were $43.06 million.
Six-month operating cash use was $16.11 million, investing cash use was $1.35 million, and financing provided $20.21 million. Cash increased $2.75 million from September 30, 2017.
Senior secured notes had $13.5 million principal due December 2018; $12.51 million was the recorded carrying amount after discount. Stockholder notes of $4.61 million were payable on demand. Capital lease obligations totaled about $4.37 million, including current and long-term portions.
Accumulated deficit was $195.7 million. The filing reports substantial doubt about the company’s ability to continue as a going concern.

Changes versus the prior comparable period

Quarterly collaboration revenue rose from $303,140 to $771,890, reflecting recognition of GMS Tenshi collaboration payments. Six-month revenue increased from $606,281 to $1.54 million.
Quarterly operating loss narrowed to $6.83 million from $7.84 million. Six-month operating loss narrowed to $10.01 million from $25.63 million, while net loss improved to $9.46 million from $27.14 million.
Six-month R&D expense fell $11.79 million, primarily because planned Phase 3 trials for ONS-3010 and ONS-1045 were postponed pending development partners, and a contract settlement reduced expense by $3.23 million. These reductions were partly offset by approximately $1.95 million of ONS-5010 development spending.
Six-month G&A expense fell $2.90 million, largely due to lower stock-based compensation and professional fees. Operating cash use, however, increased from $9.95 million to $16.11 million, largely reflecting payments of prior-period payables and accrued expenses.
The six-month common-stockholder loss includes $15.74 million of beneficial-conversion-feature charges and $1.09 million of Series A preferred dividends and related settlement; these items explain why it substantially exceeds reported net loss.

Outlook, management commentary, and risks

Management said March 31 cash plus proceeds received and expected from the May 2018 private placement were expected to fund operations through December 2018, excluding debt repayment. The company stated it would need substantial additional financing thereafter and could scale back plans or place activities on hold if funding or partnerships were not secured.
On May 14, 2018, the company received $7.5 million in the first tranche of a $15.0 million private placement with GMS Tenshi. A second $7.5 million tranche was to close beginning June 11 and no later than September 21, 2018, subject to the agreement’s terms. The first tranche included warrants for up to 10.26 million additional shares at $0.975 per share. These are subsequent events, not March 31 cash.
ONS-3010 and ONS-1045 had completed Phase 1 and were being prepared for Phase 3, contingent on a license or co-development partner. Management expected ONS-5010 to enter clinical development in 2018. The company also planned to seek contract development and manufacturing work, but reported no revenue from such services to date.
The company had no approved products and relied on financing, collaboration revenue, and future partnerships. Clinical, regulatory, competitive, commercialization, and funding outcomes remained uncertain. The filing expressly states substantial doubt about going concern; the $13.5 million notes maturity and callable stockholder notes compound liquidity risk.
The company received $3.15 million in December 2017 from selling New Jersey tax losses and credits, recorded as an income tax benefit. It also recognized a $1.25 million loss on extinguishment of debt in the six-month period after exchanging $1.5 million of notes for Series B preferred shares.
The corporate office lease was amended and accounted for as a capital lease, with an estimated $3.0 million building asset and a lease term through February 2028. The filing disclosed $15.37 million of future rental payments before $12.16 million attributed to interest.
The filing corrected an immaterial prior-period lease-accounting error that reclassified certain rent expense to interest expense. Management concluded disclosure controls were effective and reported no material changes in internal control over financial reporting.

Investor verification priorities

Confirm receipt and timing of the remaining May 2018 financing tranche, the resulting cash runway, and the company’s ability to meet the December 2018 note maturity and any demand for stockholder-note repayment.
Review the terms, conversion effects, and potential dilution from Series A and Series B preferred stock and outstanding warrants, including the May financing warrants.
Track whether ONS-3010 and ONS-1045 obtain development partners and whether ONS-5010 actually enters clinical trials; assess the funding needed to advance each program.
Assess whether contract manufacturing services or new licensing and co-development arrangements generate material cash, rather than relying on amortization of previously received collaboration payments.
Reconcile the filing’s stated cash runway with debt obligations, cash burn, and the timing and conditions of future financing proceeds.